It was reported that on (b)(6) 2019, the valve was implanted via v-p shunt to treat secondary normal pressure hydrocephalus (snph).An initial setting was 70mmh2o.On (b)(6) 2019, the patient developed vomiting and decreased activity.Ct scan was performed, and cerebral ventricular enlargement was observed; valve occlusion was suspected.On (b)(6) 2019, the valve was replaced with a new valve with no adverse consequences to the patient.
|
Updated fields: d4.D10, g4, g7, h2, h3, h4, h6, h10 udi (b)(4) the hakim valve was received for evaluation.Dhr- conformed to the specifications when released to stock.Failure analysis- the valve passed the test for programming, occlusion, leaking, reflux, and pressure.No root cause could be determined, as the technician was unable to confirm the problem reported by the customer.The possible root cause for the problem reported by the customer could have been due to blockage due to buildup of protein, no occlusion/blockage issue was noted during the investigation.Between 05nov2019 and 30jun2020, approximately 2,200 mdrs submitted electronically by integra lifesciences via trackwise, integra's complaint handling system, were not received by cdrh due to a computer system issue.Within this time period, an error with integra's middleware, which facilitates communications between trackwise and the fda system, caused the complaint records to close and indicate we had received an acknowledgement 3 from the fda when we had not.Integra interpreted the acknowledgement as a successful submission; however, subsequent investigation revealed the acknowledgement 3 received was from our middleware and not from the fda (these acknowledgements have been retained as part of the documentation of the mdr).The malfunction was related to the relocation of the trackwise application to a new data center during the transition of integra's corporate headquarters from plainsboro, nj to princeton, nj.Previously, integra had been successfully receiving acknowledgements 1, 2, and 3 from the fda, and our records reflect these acknowledgements, including the date and time stamps.Capa pr 229048 and nc 20-011 have been opened by integra to further investigate the nonconformance and develop a corrective action plan.The middleware error has been corrected, and integra has filed mdrs since the correction and verified that the appropriate acknowledgements have been received from the fda.Integra is resubmitting all impacted mdr reports for the time period 05nov2019 through 30jun2020.Integra lifesciences contacted (b)(4) office of product evaluation and quality on july 8-9, 2020 to report these issues regarding mdr reports.
|